Ophthalmic Drug Market to Exceed $40 Billion as Biologics Drive Growth
Event summary
- Visiongain projects the global ophthalmic drugs market to reach US$41.88 billion in 2026.
- The market is expected to grow at a compound annual growth rate (CAGR) of 7.9% through 2036.
- Biologic therapies, particularly anti-VEGF agents, are the primary revenue drivers in the ophthalmic drug market.
- AI-enabled retinal imaging systems are expanding patient pathways into retinal therapy markets.
- Roche’s Susvimo® Port Delivery System demonstrates industry focus on drug durability and extended refill intervals.
The big picture
The ophthalmic drug market is benefiting from an aging global population and rising prevalence of age-related eye diseases. The shift towards biologics and innovative drug delivery systems represents a significant value capture opportunity, but also introduces complexities around manufacturing, supply chain resilience, and reimbursement. The increasing adoption of AI-powered diagnostics promises to expand the addressable market, but requires careful navigation of regulatory approvals and patient access pathways.
What we're watching
- Competitive Dynamics
- The race to develop and commercialize longer-acting biologics and delivery systems will intensify, potentially reshaping the competitive landscape and impacting pricing strategies.
- Regulatory Impact
- Escalating U.S. trade tariffs on APIs could significantly affect generic and smaller specialty manufacturers, forcing them to re-evaluate sourcing and pricing models.
- Adoption Rate
- The pace at which AI-driven diagnostic tools are integrated into primary care settings will dictate the expansion of the treated population and the overall market size.
Related topics